Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:EARS

Auris Medical (EARS) Stock Price, News & Analysis

Auris Medical logo

About Auris Medical Stock (NASDAQ:EARS)

Key Stats

Today's Range
$0.43
$0.47
50-Day Range
$2.25
$3.27
52-Week Range
$0.73
$6.60
Volume
93,819 shs
Average Volume
3.10 million shs
Market Capitalization
$4.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Auris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Receive EARS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Auris Medical and its competitors with MarketBeat's FREE daily newsletter.

EARS Stock News Headlines

Envoy Medical receives FDA approval to initiate study for hearing device
Has Trump Finally Gone Too Far?
Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.
See More Headlines

EARS Stock Analysis - Frequently Asked Questions

Auris Medical Holding Ltd. (NASDAQ:EARS) announced its earnings results on Thursday, May, 11th. The biotechnology company reported ($4.40) earnings per share for the quarter, missing the consensus estimate of ($2.80) by $1.60.

Shares of Auris Medical reverse split on the morning of Wednesday, May 1st 2019. The 1-20 reverse split was announced on Tuesday, April 30th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 30th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Auris Medical investors own include Helios and Matheson Analytics (HMNY), TransEnterix (TRXDW), Novavax (NVAX), OPKO Health (OPK), Anavex Life Sciences (AVXL), Flexion Therapeutics (FLXN) and Rigel Pharmaceuticals (RIGL).

Company Calendar

Last Earnings
5/11/2017
Today
11/19/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:EARS
Fax
N/A
Employees
132,200
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.57 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.92 million
Optionable
Not Optionable
Beta
1.17
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:EARS) was last updated on 11/19/2024 by MarketBeat.com Staff
From Our Partners